MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-03-2026
Aytu BioScience Gross Profit 2011-2026 | AYTU
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Aytu BioScience
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45.8 M | 49.1 M | 66.6 M | 52.3 M | 29.2 M | 20.1 M | 5.12 M | 1.61 M | 1.8 M | 1.61 M | 174 K | 58.9 K | - | 1.75 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 66.6 M | 1.75 K | 21 M |
Quarterly Gross Profit Aytu BioScience
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.62 M | 9.19 M | - | 12.8 M | 10.8 M | 12 M | - | 10.4 M | 14.6 M | 13 M | - | 12.7 M | 17.3 M | 18 M | 35.3 M | 12.7 M | 12.3 M | 12.5 M | 24.8 M | -452 K | 8.9 M | 9.46 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 35.3 M | -452 K | 13.5 M |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
180 M | - | 2.43 % | $ 254 M |  Germany |
 |
ADMA Biologics
ADMA
|
293 M | $ 16.45 | 0.43 % | $ 3.92 B |  USA |
 |
ANI Pharmaceuticals
ANIP
|
143 M | $ 76.75 | 0.85 % | $ 1.48 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | USA |
 |
Acer Therapeutics
ACER
|
1.27 M | - | 2.71 % | $ 14 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-523 K | - | -11.43 % | $ 502 K | USA |
 |
Aptorum Group Limited
APM
|
-104 K | $ 0.83 | 4.23 % | $ 4.53 M |  China |
 |
Athersys
ATHX
|
1.44 M | - | 3.77 % | $ 22.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-428 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
4.77 M | - | - | $ 521 M | USA |
 |
BioDelivery Sciences International
BDSI
|
14 M | - | -4.8 % | $ 255 M | USA |
 |
Adverum Biotechnologies
ADVM
|
2.32 M | - | - | $ 86.2 M | USA |
 |
BridgeBio Pharma
BBIO
|
38.1 M | $ 66.98 | 3.8 % | $ 12.8 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
774 M | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
7.32 M | - | - | $ 789 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
1.07 | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
4.15 M | - | -16.75 % | $ 25.8 M | USA |
 |
BioLineRx Ltd.
BLRX
|
19.7 M | $ 2.88 | 2.51 % | $ 908 M |  Israel |
 |
Clovis Oncology
CLVS
|
123 M | - | -7.23 % | $ 13 M | USA |
 |
Acorda Therapeutics
ACOR
|
119 M | - | -24.86 % | $ 820 K | USA |
 |
BioMarin Pharmaceutical
BMRN
|
1.34 B | $ 60.75 | 3.79 % | $ 11.7 B | USA |
 |
Acasti Pharma
ACST
|
-32.3 K | - | 4.01 % | $ 150 M |  Canada |
 |
CTI BioPharma Corp.
CTIC
|
4.2 K | - | - | $ 1.2 B | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
5.88 K | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
1.94 M | - | -4.36 % | $ 27 M | USA |
 |
CureVac N.V.
CVAC
|
-10.6 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
4.73 M | - | 5.93 % | $ 314 M | Canada |
 |
Cabaletta Bio
CABA
|
0.006 | $ 3.41 | 4.77 % | $ 3.98 M | USA |
 |
Capricor Therapeutics
CAPR
|
310 | $ 25.71 | -0.5 % | $ 688 M | USA |
 |
AgeX Therapeutics
AGE
|
102 K | - | -10.17 % | $ 12.2 K | USA |
 |
Codexis
CDXS
|
52.8 M | $ 1.1 | 12.24 % | $ 80.7 M | USA |
 |
Certara
CERT
|
129 M | $ 7.33 | 1.24 % | $ 1.18 B | USA |
 |
Evofem Biosciences
EVFM
|
-22 K | - | 7.55 % | $ 38.1 M | USA |